Infective endocarditis

From WikiProjectMed
Jump to navigation Jump to search
Infective endocarditis
Other names: Bacterial endocarditis
Haemophilus parainfluenzae Endocarditis PHIL 851 lores.jpg
A mitral valve vegetation caused by bacterial endocarditis.
SpecialtyCardiology, Infectious disease
SymptomsFever, small areas of bleeding into the skin, heart murmur, feeling tired, low red blood cells[1]
ComplicationsValvular insufficiency, heart failure, stroke, kidney failure[1][2]
CausesBacterial infection, fungal infection[1]
Risk factorsValvular heart disease including rheumatic disease, congenital heart disease, artificial valves, hemodialysis, intravenous drug use, electronic pacemakers[3]
Diagnostic methodBased on symptoms, blood cultures, ultrasound[1]
TreatmentAntibiotics, heart surgery[1]
Prognosis25% risk of death[3]
Frequency5 per 100,000 per year[3]

Infective endocarditis is an infection of the inner surface of the heart, usually the valves.[1] Symptoms may include fever, small areas of bleeding into the skin, heart murmur, feeling tired, and low red blood cell count.[1] Complications may include backward blood flow in the heart, the heart struggling to pump a sufficient amount of blood to meet the body's needs (heart failure), abnormal electrical conduction in the heart, stroke, and kidney failure.[1][2]

The cause is typically a bacterial infection and less commonly a fungal infection.[1] Risk factors include valvular heart disease, including rheumatic disease, congenital heart disease, artificial valves, hemodialysis, intravenous drug use, and electronic pacemakers.[3] The bacteria most commonly involved are streptococci or staphylococci.[1] Diagnosis is suspected based on symptoms and supported by blood cultures or ultrasound of the heart.[1] There is also a noninfective form of endocarditis.[1]

The usefulness of antibiotics following dental procedures for prevention is unclear.[4] Some recommend them for people at high risk.[1] Treatment is generally with intravenous antibiotics.[1] The choice of antibiotics is based on the results of blood cultures.[1] Occasionally heart surgery is required.[1]

The number of people affected is about 5 per 100,000 per year.[3] Rates, however, vary between regions of the world.[3] Infective endocarditis occurs in males more often than in females.[1] The risk of death among those infected is about 25%.[3] Without treatment, it is almost universally fatal.[1]


Infective endocarditis is divided into the three categories of acute, subacute, and chronic based on the duration of symptoms.[5] Acute infective endocarditis refers to the presence of signs and symptoms of infective endocarditis that are present for days up to six weeks.[5] If these signs and symptoms persist for more than six weeks but less than three months, this is subacute infective endocarditis.[5] Chronic infective endocarditis refers to the presence of such signs and symptoms when they persist for more than three months.[5]

  • Subacute bacterial endocarditis (SBE) is often due to streptococci of low virulence (mainly viridans streptococci) and mild to moderate illness which progresses slowly over weeks and months (>2 weeks) and has low propensity to hematogenously seed extracardiac sites.
  • Acute bacterial endocarditis (ABE) is a fulminant illness over days to weeks (<2 weeks), and is more likely due to Staphylococcus aureus, which has much greater virulence or disease-producing capacity and frequently causes metastatic infection.[6]

This classification is now discouraged, because the ascribed associations (in terms of organism and prognosis) were not strong enough to be relied upon clinically. The terms short incubation (meaning less than about six weeks) and long incubation (greater than about six weeks) are preferred.[7]

Culture results

Infective endocarditis may also be classified as culture-positive or culture-negative. By far the most common cause of "culture-negative" endocarditis is prior administration of antibiotics.

Sometimes microorganisms can take a longer period of time to grow in the culture media, such organisms are said to be fastidious because they have demanding growth requirements. Some examples include pathogens like Aspergillus species, Brucella species, Coxiella burnetii, Chlamydia species, and HACEK bacteria. Due to delay in growth and identification in these cases, patients may be erroneously classified as "culture-negative" endocarditis.

Heart side

Endocarditis can also be classified by the side of the heart affected:

  • People who intravenously inject opioids such as heroin or methamphetamine may introduce infection which can travel to the right side of the heart, classically affecting the tricuspid valve, and most often caused by S. aureus.[6]
  • Regardless of cause, left-sided endocarditis is more common in both IV drug users and non-drug users than right-sided endocarditis.[6]

Infection setting

Another form of endocarditis is healthcare-associated endocarditis when the infecting organism is believed to be transmitted in a health care setting like hospital, dialysis unit or a residential nursing home. Nosocomial endocarditis is a form of healthcare associated endocarditis in which the infective organism is acquired during a stay in a hospital and it is usually secondary to presence of intravenous catheters, total parenteral nutrition lines, pacemakers, etc.[8]

Valve type

Finally, the distinction between native-valve endocarditis and prosthetic-valve endocarditis is clinically important. Prosthetic valve endocarditis can be early (< 60 days of valvular surgery), intermediate (60 days to 1 year) or late (> 1 year following valvular surgery).

  • Early prosthetic valve endocarditis is usually due to intraoperative contamination or a postoperative bacterial contamination which is usually nosocomial in nature.
  • Late prosthetic valve endocarditis is usually due to community acquired microorganisms.[8]

Prosthetic valve endocarditis is commonly caused by Staphylococcus epidermidis as it is capable of growing as a biofilm on plastic surfaces.[9]

Signs and symptoms


Many microorganisms can cause infective endocarditis. These are generally isolated by blood culture, where the patient's blood is drawn and any growth is noted and identified. The term bacterial endocarditis (BE) commonly is used, reflecting the fact that most cases of IE are due to bacteria; however, infective endocarditis (IE) has become the preferred term.


Staphylococcus aureus is the leading cause of infective endocarditis in most parts of the world and is responsible for about 31% of cases.[5] Viridans streptococci and Enterococci are the second and third most common organisms responsible for infective endocarditis.[5] Other Streptococci are also a frequent cause. Staphylococcus aureus is the most common cause of endocarditis in people who use intravenous drugs.[12] Viridans streptococci are a common cause of infective endocarditis in South America. Infective endocarditis due to Streptococcus bovis occurs more commonly in Europe than in North America.[5] HACEK group of bacteria are also rare causes of infective endocarditis in North America.[13]

The viridans group includes S. oralis, S. mitis, S. sanguis, S. gordonii and S. parasanguis. The primary habitats for these organisms are the oral cavity and upper respiratory tract.[14] These bacteria are present in the normal oral flora and enter the bloodstream due to disruption of tissues in the mouth when dental surgical procedures are performed (tooth extractions) or genitourinary manipulation. Similarly, HACEK organisms are a group of bacteria that live on the dental gums, and can be seen with IV drug users who contaminate their needles with saliva. Patients may also have a history of poor dental hygiene, or pre-existing valvular disease.[15]

Viridans alpha-hemolytic streptococci, that are present in the mouth, are the most frequently isolated microorganisms when the infection is acquired in a community setting. In contrast, Staphylococcus blood stream infections are frequently acquired in a health care setting where they can enter the blood stream through procedures that cause break in the integrity of skin, such as surgery, catheterization, or during access of long term indwelling catheters or secondary to intravenous injection of recreational drugs.

Enterococcus can enter the bloodstream as a consequence of abnormalities in the gastrointestinal or genitourinary tracts.

Some organisms, when isolated, give valuable clues to the cause, as they tend to be specific.

  • Pseudomonas species, which are very resilient organisms that thrive in water, may contaminate street drugs that have been contaminated with drinking water. P. aeruginosa can infect a child through foot punctures, and can cause both endocarditis and septic arthritis.[16]
  • S. bovis and Clostridium septicum, which are part of the natural flora of the bowel, are associated with colon cancers. When they present as the causative agent in endocarditis, it usually prompts a colonoscopy to be done immediately due to concerns regarding spread of bacteria from the colon through the bloodstream due to the cancer breaking down the barrier between the inside of the colon (lumen) and the blood vessels which drain the bowel.[17][18]
  • Less commonly reported bacteria responsible for so called "culture negative endocarditis" include Bartonella, Chlamydia psittaci, and Coxiella.[19] Such bacteria can be identified by serology, culture of the excised valve tissue, sputum, pleural fluid, and emboli, and by polymerase chain reaction or sequencing of bacterial 16S ribosomal RNA.

Multiple case reports of infective endocarditis caused by unusual organisms have been published. Cutibacterium sp., which are normal skin flora, have been responsible for infective endocarditis sometimes leading to deaths due to the indolent course of this abscess-producing infection.[20]Tropheryma whipplei has caused endocarditis without gastrointestinal involvement.[21] Citrobacter koseri was found in an immunocompetent adult.[22] Neisseria bacilliformis was found in a person with a bicuspid aortic valve.[23]


Fungal endocarditis (FE) is an often fatal and one of the most serious forms of infective endocarditis. The types of fungi most seen associated with this disease are:

Candida albicans is found as a spherical or oval budding yeast. It is associated with endocarditis in IV drug users, patients with prosthetic valves, and immunocompromised patients. It forms biofilms around thick-walled resting structures like prosthetic heart valves and additionally colonizes and penetrates endothelial walls.[24] C. albicans is responsible for 24-46% of all the cases of FE, and its mortality rate is 46.6–50%.[25]

Other fungi demonstrated to cause endocarditis are Histoplasma capsulatum and Aspergillus.[19] Aspergillus contributes to roughly 25% of FE cases.[25] Endocarditis with Tricosporon asahii has also been reported in a case report.[26]

Risk factors

Risk factors for infective endocarditis are based on the premise that in a healthy individual, bacteremia (bacteria entering the blood stream) is cleared quickly with no adverse consequences.[27] However, if a heart valve is damaged, the bacteria can attach themselves to the valve, resulting in infective endocarditis. Additionally, in individuals with weakened immune systems, the concentration of bacteria in the blood can reach levels high enough to increase the probability that some will attach to the valve. Some significant risk factors are listed here:[5][27]

More detailed descriptions of these and other risk factors are provided below.

Other conditions that result in large numbers of bacteria entering into the bloodstream include colorectal cancer (mostly Streptococcus bovis),[17] serious urinary tract infections (mostly enterococci), and drug injection (Staphylococcus aureus). With a large number of bacteria, even a normal heart valve may become infected.

A more virulent organism (such as Staphylococcus aureus) can cause infective endocarditis by infecting even a normal heart valve.

Intravenous drug users tend to get their right-sided heart valves infected because the veins that are injected drain into the right side of the heart. In rheumatic heart disease, infection occurs on the aortic and the mitral valves on the left side of the heart.

Other factors that increase the risk of developing infective endocarditis are low levels of white blood cells, immunodeficiency or immunosuppression, malignancy, diabetes mellitus, and alcohol abuse.[6]

Dental operations

In the past, one in eight cases[24] of infective endocarditis were because of bacteremia caused by dental procedures (in most cases due to Streptococcus viridans, which reside in the oral cavity), such as a cleaning or extraction of a tooth; this was thought to be more clinically significant than it actually was. However, it is important that a dentist or a dental hygienist be told of any heart problems before commencing treatment. Antibiotics are administered to patients with certain heart conditions as a precaution, although this practice has changed in the US, with new American Heart Association guidelines released in 2007,[28] and in the UK as of March 2008 due to new NICE guidelines. Everyday tooth brushing and flossing will similarly cause bacteremia, so a high standard of oral health should be adhered to at all times.[24] Although there is little evidence to support antibiotic prophylaxis for dental treatment, the current American Heart Association guidelines are highly accepted by clinicians[29] and patients.[30]


Drawing of endocarditis.

Damaged valves and endocardium contribute to the development of infective endocarditis.[27] Specifically, the damaged part of a heart valve forms a local blood clot, a condition known as non-bacterial thrombotic endocarditis (NBTE). The platelet and fibrin deposits that form as part of the blood clotting process allow bacteria to take hold and form vegetations. As previously mentioned, the body has no direct methods of combating valvular vegetations because the valves do not have a dedicated blood supply. This combination of damaged valves, bacterial growth, and lack of a strong immune response results in infective endocarditis.

Damage to the valves and endocardium can be caused by:[27]

  • Altered, turbulent blood flow. The areas that fibrose, clot, or roughen as a result of this altered flow are known as jet lesions. Altered blood flow is more likely in high pressure areas, so ventricular septal defects or patent ductus arteriosus can create more susceptibility than atrial septal defects.
  • Catheters, electrodes, and other intracardiac prosthetic devices.
  • Solid particles from repeated intravenous injections.
  • Chronic inflammation. Examples include auto-immune mechanisms and degenerative valvular lesions.

The risk factors for infective endocarditis provide a more extensive list of conditions that can damage the heart.


Vegetation on the tricuspid valve by echocardiography. Arrow denotes the vegetation.

In general, the Duke criteria should be fulfilled in order to establish the diagnosis of endocarditis.[5][31] Although the Duke criteria are widely used, they have significant limitations.[5] For example, the sensitivity of the Duke criteria for detecting infective endocarditis decreases when prosthetic heart valves are present.[5]

As the Duke criteria rely heavily on the results of echocardiography, research has addressed when to order an echocardiogram by using signs and symptoms to predict occult endocarditis among patients with intravenous drug abuse[32][33][34] and among non drug-abusing patients.[35][36] However, this research is over twenty years old and it is possible that changes in the epidemiology of endocarditis and bacteria such as staphylococci make the following estimates incorrect.

The blood tests C reactive protein (CRP) and procalcitonin have not been found to be particularly useful in helping make or rule out the diagnosis.[37]


Echocardiography is the main type of diagnostic imaging used to establish the diagnosis of infective endocarditis.[5] There are two main types of echocardiography used to assist with the diagnosis of IE: transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE).[5] The transthoracic echocardiogram has a sensitivity and specificity of approximately 65% and 95% if the echocardiographer believes there is 'probable' or 'almost certain' evidence of endocarditis.[38][39] However, TTE only has a sensitivity of approximately 50% in people with prosthetic valve endocarditis whereas TEE has a sensitivity exceeding 90% in these individuals.[5] The TEE also has an important diagnostic role when the TTE does not reveal evidence of IE but the diagnostic suspicion remains high since TEE is more sensitive for IE than TTE and is better able to characterize the local damage IE causes to the heart valves and surrounding tissues.[5] Guidelines support the initial use of TTE over TEE as an imaging modality in people with positive blood cultures, a new heart murmur, and suspected infective endocarditis.[5] TEE is the preferred initial form of imaging in people with suspected infective endocarditis who have a moderate to high pretest probability of infective endocarditis, including people with prosthetic heart valves, blood cultures growing Staphylococcus, or have an intracardiac device (such as a pacemaker).[5]

Modified Duke criteria

Established in 1994 by the Duke Endocarditis Service and revised in 2000, the Duke criteria are a collection of major and minor criteria used to establish a diagnosis of infective endocarditis.[31][42] According to the Duke criteria, diagnosis of infective endocarditis can be definite, possible, or rejected.[27] A diagnosis of infective endocarditis is definite if either the following pathological or clinical criteria are met:

One of these pathological criteria:

  • Histology or culture of a cardiac vegetation, an embolized vegetation, or intracardiac abscess from the heart finds microorganisms
  • Active endocarditis

One of these combinations of clinical criteria

  • Two major clinical criteria
  • One major and three minor criteria
  • Five minor criteria

Diagnosis of infective endocarditis is possible if one of the following combinations of clinical criteria are met:

  • One major and one minor criteria
  • Three minor criteria are fulfilled

Major criteria

Positive blood culture with typical IE microorganism, defined as one of the following:[27]

  • Typical microorganism consistent with IE from two separate blood cultures, as noted below:
  • Microorganisms consistent with IE from persistently positive blood cultures defined as:
    • Two positive cultures of blood samples drawn >12 hours apart, or
    • Three or a majority of ≥four separate blood cultures (with first and last sample drawn at least one hour apart)
    • Coxiella burnetii detected by at least one positive blood culture or IgG antibody titer for Q fever phase 1 antigen >1:800. This was previously a minor criterion

Evidence of endocardial involvement with positive echocardiogram defined as

  • Oscillating intracardiac mass on valve or supporting structures, in the path of regurgitant jets, or on implanted material in the absence of an alternative anatomic explanation, or
  • Abscess, or
  • New partial dehiscence of prosthetic valve or new valvular regurgitation (worsening or changing of preexisting murmur not sufficient)

Minor criteria


Among people who do not use intravenous drugs and have a fever in the emergency department, there is a less than 5% chance of occult endocarditis. Mellors in 1987 found no cases of endocarditis nor of staphylococcal bacteremia among 135 febrile patients in the emergency room.[36] The upper confidence interval for 0% of 135 is 5%, so for statistical reasons alone, there is up to a 5% chance of endocarditis among these patients. In contrast, Leibovici found that among 113 non-selected adults admitted to the hospital because of fever there were two cases (1.8% with 95%CI: 0% to 7%) of endocarditis.[35]

Among people who do use intravenous drugs and have a fever in the emergency department, there is about a 10% to 15% prevalence of endocarditis. This estimate is not substantially changed by whether the doctor believes the patient has a trivial explanation for their fever.[34] Weisse found that 13% of 121 patients had endocarditis.[32] Marantz also found a prevalence of endocarditis of 13% among such patients in the emergency department with fever.[34] Samet found a 6% incidence among 283 such patients, but after excluding patients with initially apparent major illness to explain the fever (including 11 cases of manifest endocarditis), there was a 7% prevalence of endocarditis.[33]

Among people with staphylococcal bacteremia (SAB), one study found a 29% prevalence of endocarditis in community-acquired SAB versus 5% in nosocomial SAB.[43] However, only 2% of strains were resistant to methicillin and so these numbers may be low in areas of higher resistance.


Not all people with heart disease require antibiotics to prevent infective endocarditis. Heart diseases have been classified into high, medium and low risk of developing IE. Those falling into high risk category require IE prophylaxis before endoscopies and urinary tract procedures. Diseases listed under high risk include:

  • Prior endocarditis
  • Unrepaired cyanotic congenital heart diseases
  • Completely repaired congenital heart disease in their first 6 months
  • Prosthetic heart valves
  • Incompletely repaired congenital heart diseases
  • Cardiac transplant valvulopathy

Following are the antibiotic regimens recommended by the American Heart Association for antibiotic prophylaxis:[28]

Oral amoxicillin one hour before the procedure
Intravenous or intramuscular ampicillin one hour before the procedure
In patients allergic to penicillins
Azithromycin or clarithromycin orally one hour before the procedure
Cephalexin orally one hour before the procedure
Clindamycin orally one hour before the procedure

In the UK, NICE clinical guidelines no longer advise prophylaxis because there is no clinical evidence that it reduces the incidence of IE and there are negative effects (e.g. allergy and increased bacterial resistance) of taking antibiotics that may outweigh the benefits.[44]

Antibiotics were historically commonly recommended to prevent IE in those with heart problems undergoing dental procedures (known as dental antibiotic prophylaxis). There is, however, insufficient evidence to support whether antibiotics are effective or ineffective at preventing IE when given prior to a dental procedures in people at high risk.[45] They are less commonly recommended for this procedure.[46]

In some countries e.g. the USA, high risk patients may be given prophylactic antibiotics such as penicillin or clindamycin for penicillin-allergic people prior to dental procedures.[14] Prophylactics should be bactericidal rather than bacteriostatic.[14] Such measures are not taken in certain countries e.g. Scotland due to the fear of antibiotic resistance.[47] Because bacteria are the most common cause of infective endocarditis, antibiotics such as penicillin[14] and amoxicillin (for beta lactamase-producing bacteria) are used in prophylaxis.


High-dose antibiotics are the cornerstone of treatment for infective endocarditis. These antibiotics are administered by the intravenous (IV) route to maximize diffusion of antibiotic molecules into vegetation(s) from the blood filling the chambers of the heart. This is necessary because neither the heart valves nor the vegetations adhering to them are supplied by blood vessels. Antibiotics are typically continued for two to six weeks depending on the characteristics of the infection and the causative microorganisms. Antibiotic treatment lowers the risk of embolic complications in people with infective endocarditis.[5]

In acute endocarditis, due to the fulminant inflammation, empirical antibiotic therapy is started immediately after the blood has been drawn for culture to clarify the bacterial organisms responsible for the infection. This usually includes vancomycin and ceftriaxone IV infusions until the infecting organism is identified and the susceptibility report with the minimum inhibitory concentration becomes available. Once this information is available, this allows the supervising healthcare professional to modify the antimicrobial therapy to target the specific infecting microorganism. The routine use of gentamicin to treat endocarditis has fallen out of favor due to the lack of evidence to support its use (except in infections caused by Enterococcus and nutritionally variant streptococci) and the high rate of complications.[48] In cases of subacute endocarditis, where the person's hemodynamic status is usually stable, antibiotic treatment can be delayed until the causative microorganism can be identified.

Viridans group streptococci and Streptococcus bovis are usually highly susceptible to penicillin and can be treated with penicillin or ceftriaxone.[49] Relatively resistant strains of viridans group streptococci and Streptococcus bovis are treated with penicillin or ceftriaxone along with a shorter two-week course of an aminoglycoside during the initial phase of treatment.[49] Highly penicillin-resistant strains of viridans group streptococci, nutritionally variant streptococci like Granulicatella sp., Gemella sp., Abiotrophia defectiva,[50] and Enterococci are usually treated with a combination therapy consisting of penicillin and an aminoglycoside for the entire duration of 4–6 weeks.[49]

Some people may be treated with a relatively shorter course of treatment[49] (two weeks) with benzyl penicillin IV if infection is caused by viridans group streptococci or Streptococcus bovis as long as the following conditions are met:

  • Endocarditis of a native valve, not of a prosthetic valve
  • A MIC ≤ 0.12 mg/l
  • A complication such as heart failure, arrhythmia, or pulmonary embolism occurs
  • No evidence of extracardiac complication like septic thromboembolism
  • No vegetations > 5 mm in diameter conduction defects
  • Rapid clinical response and clearance of blood stream infection

Additionally, oxacillin-susceptible Staphylococcus aureus native valve endocarditis of the right side can also be treated with a short 2-week course of a beta-lactam antibiotic such as nafcillin with or without aminoglycosides.

Surgical debridement of infected material and replacement of the valve with a mechanical or bioprosthetic artificial heart valve is necessary in certain situations:[51]

  • Patients with significant valve stenosis or regurgitation causing heart failure
  • Evidence of hemodynamic compromise in the form of elevated end-diastolic left ventricular or left atrial pressure or moderate to severe pulmonary hypertension
  • Presence of intracardiac complications like paravalvular abscess, conduction defects or destructive penetrating lesions
  • Recurrent septic emboli despite appropriate antibiotic treatment
  • Large vegetations (> 10 mm)
  • Persistently positive blood cultures despite appropriate antibiotic treatment
  • Prosthetic valve dehiscence
  • Relapsing infection in the presence of a prosthetic valve
  • Abscess formation
  • Early closure of mitral valve
  • Infection caused by fungi or resistant Gram negative bacteria.

The guidelines were recently updated by both the American College of Cardiology and the European Society of Cardiology. There was a recent meta-analysis published that showed surgical intervention at seven days or less is associated with lower mortality.[52]


Infective endocarditis is associated with 18% in-hospital mortality.[13] As many as 50% of people with infective endocarditis may experience embolic complications.[5]


In developed countries, the annual incidence of infective endocarditis is 3 to 9 cases per 100,000 persons.[27] Infective endocarditis occurs more often in men than in women.[5] There is an increased incidence of infective endocarditis in persons 65 years of age and older, which is probably because people in this age group have a larger number of risk factors for infective endocarditis. In recent years, over one-third of infective endocarditis cases in the United States were healthcare-associated.[27] Another trend observed in developed countries is that chronic rheumatic heart disease accounts for less than 10% of cases. Although a history of valve disease has a significant association with infective endocarditis, 50% of all cases develop in people with no known history of valvular disease.


Lazare Riviére first described infective endocarditis affecting the aortic valve in 1616.[5] In 1806, Jean-Nicolas Corvisart coined the term vegetation to describe collections of debris found on a mitral valve affected by infective endocarditis.[5] The British physician Joseph Hodgson was the first to describe the embolic complications of infective endocarditis in 1815.[5] It was not until 1878 that Theodor Klebs first suggested that infective endocarditis had a microbial infectious origin.[5] In 1909, William Osler noted that heart valves that experienced degeneration and were sclerotic or poorly functioning had a higher risk of being affected.[5] Later, in 1924, Emanuel Libman and Benjamin Sacks described cases of vegetative endocarditis that lacked a clear microbial origin and were often associated with the autoimmune condition systemic lupus erythematosus.[5] In 1944, physicians reported on the first successful use of penicillin to treat a case of infective endocarditis.[5]


  1. 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 "Infective Endocarditis – Cardiovascular Disorders". Merck Manuals Professional Edition. September 2017. Archived from the original on 2 May 2020. Retrieved 11 December 2017.
  2. 2.0 2.1 Njuguna B, Gardner A, Karwa R, Delahaye F (February 2017). "Infective Endocarditis in Low- and Middle-Income Countries". Cardiology Clinics. 35 (1): 153–163. doi:10.1016/j.ccl.2016.08.011. hdl:1805/14046. PMID 27886786.
  3. 3.0 3.1 3.2 3.3 3.4 3.5 3.6 Ambrosioni J, Hernandez-Meneses M, Téllez A, Pericàs J, Falces C, Tolosana JM, Vidal B, Almela M, Quintana E, Llopis J, Moreno A, Miro JM (May 2017). "The Changing Epidemiology of Infective Endocarditis in the Twenty-First Century". Current Infectious Disease Reports. 19 (5): 21. doi:10.1007/s11908-017-0574-9. PMID 28401448. S2CID 24935834.
  4. Cahill TJ, Harrison JL, Jewell P, Onakpoya I, Chambers JB, Dayer M, Lockhart P, Roberts N, Shanson D, Thornhill M, Heneghan CJ, Prendergast BD (June 2017). "Antibiotic prophylaxis for infective endocarditis: a systematic review and meta-analysis" (PDF). Heart. 103 (12): 937–944. doi:10.1136/heartjnl-2015-309102. PMID 28213367. S2CID 25918810. Archived (PDF) from the original on 2018-07-23. Retrieved 2019-07-13.
  5. 5.00 5.01 5.02 5.03 5.04 5.05 5.06 5.07 5.08 5.09 5.10 5.11 5.12 5.13 5.14 5.15 5.16 5.17 5.18 5.19 5.20 5.21 5.22 5.23 5.24 5.25 5.26 5.27 Hubers, SA; DeSimone, DC; Gersh, BJ; Anavekar, NS (May 2020). "Infective Endocarditis: A Contemporary Review". Mayo Clinic Proceedings. 95 (5): 982–997. doi:10.1016/j.mayocp.2019.12.008. PMID 32299668.
  6. 6.0 6.1 6.2 6.3 6.4 Mitchell RS, Kumar V, Robbins SL, Abbas AK, Fausto N (2007). Robbins Basic Pathology (8th ed.). Saunders/Elsevier. pp. 406–8. ISBN 978-1-4160-2973-1.
  7. Morris AM (January 2006). "How best to deal with endocarditis". Current Infectious Disease Reports. 8 (1): 14–22. doi:10.1007/s11908-006-0030-8. PMID 16448596. S2CID 10450799.
  8. 8.0 8.1 Kasper DL, Brunwald E, Fauci AS, Hauser S, Longo DL, Jameson JL (2005). Harrison's Principles of Internal Medicine. McGraw-Hill. pp. 731–40. ISBN 978-0-07-139140-5. OCLC 54501403.{{cite book}}: CS1 maint: multiple names: authors list (link)
  9. Otto M (2009), "Staphylococcus epidermidis — the 'accidental' pathogen", Nature Reviews Microbiology, 7 (8): 555–567, doi:10.1038/nrmicro2182, PMC 2807625, PMID 19609257
  10. 10.0 10.1 Mattu, Amal; Goyal, Deepi; Barrett, Jeffrey W.; Broder, Joshua; DeAngelis, Michael; Deblieux, Peter; Garmel, Gus M.; Harrigan, Richard; Karras, David; L'Italien, Anita; Manthey, David (2007). Emergency medicine: avoiding the pitfalls and improving the outcomes. Blackwell/BMJ Books. p. 63. ISBN 978-1-4051-4166-6.
  11. Ferro JM, Fonseca AC (2014). "Infective endocarditis". Neurologic Aspects of Systemic Disease Part I. Handbook of Clinical Neurology. Vol. 119. pp. 75–91. doi:10.1016/B978-0-7020-4086-3.00007-2. ISBN 9780702040863. PMID 24365290.
  12. Chan, Kwan-Leung; Embil, John M. (2016). Endocarditis: Diagnosis and Management. Springer. p. 39. ISBN 978-3-319-27784-4. Archived from the original on 2020-07-24. Retrieved 2020-07-22.
  13. 13.0 13.1 Murdoch DR, Corey GR, Hoen B, Miró JM, Fowler VG, Bayer AS, Karchmer AW, Olaison L, Pappas PA, Moreillon P, Chambers ST, Chu VH, Falcó V, Holland DJ, Jones P, Klein JL, Raymond NJ, Read KM, Tripodi MF, Utili R, Wang A, Woods CW, Cabell CH (March 2009). "Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study". Archives of Internal Medicine. 169 (5): 463–73. doi:10.1001/archinternmed.2008.603. PMC 3625651. PMID 19273776.
  14. 14.0 14.1 14.2 14.3 Jeremy., Bagg (2006). Essentials of microbiology for dental students (2nd ed.). Oxford: Oxford University Press. ISBN 9780198564898. OCLC 61756542.
  15. HACEK Group Infections at eMedicine
  16. "Pseudomonas aeruginosa". Topics in Infectious Diseases Newsletter. August 2001. Archived from the original on July 24, 2008.
  17. 17.0 17.1 Gold JS, Bayar S, Salem RR (July 2004). "Association of Streptococcus bovis bacteremia with colonic neoplasia and extracolonic malignancy". Archives of Surgery. 139 (7): 760–5. doi:10.1001/archsurg.139.7.760. PMID 15249410.
  18. Chew SS, Lubowski DZ (November 2001). "Clostridium septicum and malignancy". ANZ Journal of Surgery. 71 (11): 647–9. doi:10.1046/j.1445-1433.2001.02231.x. PMID 11736823.
  19. 19.0 19.1 Lamas CC, Eykyn SJ (March 2003). "Blood culture negative endocarditis: analysis of 63 cases presenting over 25 years". Heart. 89 (3): 258–62. doi:10.1136/heart.89.3.258. PMC 1767579. PMID 12591823.
  20. Clayton JJ, Baig W, Reynolds GW, Sandoe JA (August 2006). "Endocarditis caused by Propionibacterium species: a report of three cases and a review of clinical features and diagnostic difficulties". Journal of Medical Microbiology. 55 (Pt 8): 981–7. doi:10.1099/jmm.0.46613-0. PMID 16849716.
  21. Dreier J, Szabados F, von Herbay A, Kröger T, Kleesiek K (October 2004). "Tropheryma whipplei Infection of an acellular porcine heart valve bioprosthesis in a patient who did not have intestinal Whipple's disease". Journal of Clinical Microbiology. 42 (10): 4487–93. doi:10.1128/JCM.42.10.4487-4493.2004. PMC 522317. PMID 15472298.
  22. Dzeing-Ella A, Szwebel TA, Loubinoux J, Coignard S, Bouvet A, Le Jeunne C, Aslangul E (December 2009). "Infective endocarditis due to Citrobacter koseri in an immunocompetent adult". Journal of Clinical Microbiology. 47 (12): 4185–6. doi:10.1128/JCM.00957-09. PMC 2786675. PMID 19812281.
  23. Masliah-Planchon J, Breton G, Jarlier V, Simon A, Benveniste O, Herson S, Drieux L (June 2009). "Endocarditis due to Neisseria bacilliformis in a patient with a bicuspid aortic valve". Journal of Clinical Microbiology. 47 (6): 1973–5. doi:10.1128/JCM.00026-09. PMC 2691068. PMID 19386832.
  24. 24.0 24.1 24.2 Jeremy., Bagg (2006). Essentials of microbiology for dental students (2nd ed.). Oxford: Oxford University Press. ISBN 978-0198564898. OCLC 61756542.
  25. 25.0 25.1 Yuan SM (2016). "Fungal Endocarditis". Brazilian Journal of Cardiovascular Surgery. 31 (3): 252–255. doi:10.5935/1678-9741.20160026. PMC 5062704. PMID 27737409.
  26. Izumi K, Hisata Y, Hazama S (October 2009). "A rare case of infective endocarditis complicated by Trichosporon asahii fungemia treated by surgery". Annals of Thoracic and Cardiovascular Surgery. 15 (5): 350–3. PMID 19901894.
  27. 27.0 27.1 27.2 27.3 27.4 27.5 27.6 27.7 Hoen B, Duval X (April 2013). "Clinical practice. Infective endocarditis". The New England Journal of Medicine. 368 (15): 1425–33. doi:10.1056/NEJMcp1206782. PMID 23574121.
  28. 28.0 28.1 Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, et al. (October 2007). "Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group". Circulation. 116 (15): 1736–54. doi:10.1161/CIRCULATIONAHA.106.183095. PMID 17446442. Archived from the original on 2020-05-26. Retrieved 2009-01-21.
  29. Zadik Y, Findler M, Livne S, Levin L, Elad S (December 2008). "Dentists' knowledge and implementation of the 2007 American Heart Association guidelines for prevention of infective endocarditis". Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics. 106 (6): e16–9. doi:10.1016/j.tripleo.2008.08.009. PMID 19000604. Archived from the original on 2019-12-08. Retrieved 2011-05-20.
  30. Elad S, Binenfeld-Alon E, Zadik Y, Aharoni M, Findler M (March 2011). "Survey of acceptance of the 2007 American Heart Association guidelines for the prevention of infective endocarditis: a pilot study". Quintessence International. 42 (3): 243–51. PMID 21465012. Archived from the original on 2015-12-22.
  31. 31.0 31.1 Durack DT, Lukes AS, Bright DK (March 1994). "New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service". The American Journal of Medicine. 96 (3): 200–9. doi:10.1016/0002-9343(94)90143-0. PMID 8154507.
  32. 32.0 32.1 Weisse AB, Heller DR, Schimenti RJ, Montgomery RL, Kapila R (March 1993). "The febrile parenteral drug user: a prospective study in 121 patients". The American Journal of Medicine. 94 (3): 274–80. doi:10.1016/0002-9343(93)90059-X. PMID 8452151.
  33. 33.0 33.1 Samet JH, Shevitz A, Fowle J, Singer DE (July 1990). "Hospitalization decision in febrile intravenous drug users". The American Journal of Medicine. 89 (1): 53–7. doi:10.1016/0002-9343(90)90098-X. PMID 2368794.
  34. 34.0 34.1 34.2 Marantz PR, Linzer M, Feiner CJ, Feinstein SA, Kozin AM, Friedland GH (June 1987). "Inability to predict diagnosis in febrile intravenous drug abusers". Annals of Internal Medicine. 106 (6): 823–8. doi:10.7326/0003-4819-106-6-823. PMID 3579068.
  35. 35.0 35.1 Leibovici L, Cohen O, Wysenbeek AJ (June 1990). "Occult bacterial infection in adults with unexplained fever. Validation of a diagnostic index". Archives of Internal Medicine. 150 (6): 1270–2. doi:10.1001/archinte.150.6.1270. PMID 2353860.
  36. 36.0 36.1 Mellors JW, Horwitz RI, Harvey MR, Horwitz SM (April 1987). "A simple index to identify occult bacterial infection in adults with acute unexplained fever". Archives of Internal Medicine. 147 (4): 666–71. doi:10.1001/archinte.147.4.666. PMID 3827454.
  37. Yu CW, Juan LI, Hsu SC, Chen CK, Wu CW, Lee CC, Wu JY (June 2013). "Role of procalcitonin in the diagnosis of infective endocarditis: a meta-analysis". The American Journal of Emergency Medicine. 31 (6): 935–41. doi:10.1016/j.ajem.2013.03.008. PMID 23601504.
  38. Shively BK, Gurule FT, Roldan CA, Leggett JH, Schiller NB (August 1991). "Diagnostic value of transesophageal compared with transthoracic echocardiography in infective endocarditis". Journal of the American College of Cardiology. 18 (2): 391–7. doi:10.1016/0735-1097(91)90591-V. PMID 1856406.
  39. Erbel R, Rohmann S, Drexler M, Mohr-Kahaly S, Gerharz CD, Iversen S, Oelert H, Meyer J (January 1988). "Improved diagnostic value of echocardiography in patients with infective endocarditis by transoesophageal approach. A prospective study". European Heart Journal. 9 (1): 43–53. doi:10.1093/oxfordjournals.eurheartj.a062389. PMID 3345769.
  40. 40.0 40.1 40.2 "UOTW #27 – Ultrasound of the Week". Ultrasound of the Week. 26 November 2014. Archived from the original on 9 May 2017. Retrieved 27 May 2017.
  41. "UOTW #60 – Ultrasound of the Week". Ultrasound of the Week. 5 October 2015. Archived from the original on 9 May 2017. Retrieved 27 May 2017.
  42. Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG, Ryan T, Bashore T, Corey GR (April 2000). "Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis". Clinical Infectious Diseases. 30 (4): 633–8. doi:10.1086/313753. PMID 10770721.
  43. Kaech C, Elzi L, Sendi P, Frei R, Laifer G, Bassetti S, Fluckiger U (April 2006). "Course and outcome of Staphylococcus aureus bacteraemia: a retrospective analysis of 308 episodes in a Swiss tertiary-care centre". Clinical Microbiology and Infection. 12 (4): 345–52. doi:10.1111/j.1469-0691.2005.01359.x. PMID 16524411.
  44. "Prophylaxis against infective endocarditis: Antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures". NICE Clinical Guidelines. National Institute for Health Care and Excellence (UK). March 2008. Archived from the original on 2013-01-26. Retrieved 2013-04-30.
  45. Glenny AM, Roberts GJ, Hooper L, Worthington HV (2013). "Antibiotics for the prophylaxis of bacterial endocarditis in dentistry". Cochrane Database of Systematic Reviews (10): CD003813. doi:10.1002/14651858.CD003813.pub4. PMID 24108511 – via Cochrane.
  46. "Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures". National Institute for Health and Care Excellence (NICE). 2008.
  47. "Drug Prescribing". SDCEP. Archived from the original on 2020-05-13. Retrieved 2018-01-25.
  48. Cosgrove SE, Vigliani GA, Fowler VG, Abrutyn E, Corey GR, Levine DP, Rupp ME, Chambers HF, Karchmer AW, Boucher HW (March 2009). "Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic". Clinical Infectious Diseases. 48 (6): 713–21. doi:10.1086/597031. PMID 19207079.
  49. 49.0 49.1 49.2 49.3 Baddour LM, Wilson WR, Bayer AS, Fowler VG, Bolger AF, Levison ME, et al. (June 2005). "Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America". Circulation. 111 (23): e394–434. doi:10.1161/CIRCULATIONAHA.105.165564. PMID 15956145.
  50. Kalavakunta JK, Davenport DS, Tokala H, King A, Khagny M, Gupta V (January 2011). "Destructive Abiotrophia defectiva endocarditis". The Journal of Heart Valve Disease. 20 (1): 111–2. PMID 21404910.
  51. Bonow RO, Carabello BA, Chatterjee K, de Leon AC, Faxon DP, Freed MD, et al. (September 2008). "2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons". Journal of the American College of Cardiology. 52 (13): e1–142. doi:10.1016/j.jacc.2008.05.007. PMID 18848134.
  52. Anantha Narayanan M, Mahfood Haddad T, Kalil AC, Kanmanthareddy A, Suri RM, Mansour G, Destache CJ, Baskaran J, Mooss AN, Wichman T, Morrow L, Vivekanandan R (2016). "Early versus late surgical intervention or medical management for infective endocarditis: a systematic review and meta-analysis". Heart. 102 (12): 950–7. doi:10.1136/heartjnl-2015-308589. PMID 26869640. S2CID 12007082.{{cite journal}}: CS1 maint: multiple names: authors list (link)

External links

External resources

Infective endocarditis at Curlie